Azevedo Felipe M, Oliveira Cristino C, Evangelista Deborah G, Jesus Luciana A S, Cabral Leandro F, Pereira Adriano L, Santos Larissa T, Santiago Raphael A, Cabral Laura A, José Anderson, Malaguti Carla
Postgraduate Program on Rehabilitation Sciences and Physical Function Performance, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil; and National Institute of Cardiology, Rio de Janeiro, Brazil.
Postgraduate Program on Rehabilitation Sciences and Physical Function Performance, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil; and Department of Physiotherapy, Federal University of Juiz de Fora, Campus Governador Valadares, Governador Valadares, Minas Gerais, Brazil.
Respir Care. 2023 Jan 30;68(2):208-216. doi: 10.4187/respcare.10255.
Mobility is human body movement in all its forms, including bed-to-chair transfer, walking, daily tasks, participating in work and social functions, exercising, and using public transport. The mobility of people living with COPD is affected negatively by the disease symptoms. However, limited data are available on the life-space mobility in people with COPD on long-term oxygen therapy (LTOT). This study aimed to explore the life-space mobility in subjects with COPD on LTOT and verify whether life-space mobility is associated with comorbidities and symptoms, activity in daily life, exercise capacity performance, and quality of life.
This cross-sectional study enrolled 61 subjects with COPD on LTOT (73.0 ± 8.8 y, FEV 41.7 ± 16.0% predicted, on LTOT for 2.8 ± 3.3 y). Life-space mobility (Life-Space Assessment), LTOT usage time, comorbidities (Charlson comorbidity index), need for support from a caregiver, exercise capacity (6-min step test), dyspnea (modified Medical Research Council scale), activities of daily living (ADLs, Katz scale), and health-related quality of life (EuroQol 5-Dimension Questionnaire) were assessed.
Mobility restriction was identified in 90% of participants. Life-space mobility was negatively associated with the number of comorbidities (r = -0.31, = .02), dyspnea symptom (r = -0.60, < .001), and positively associated with basic ADLs performance (r = 0.59, < .001) and exercise capacity (r = 0.49, < .001). Dyspnea and exercise capacity were independent predictors of vital space mobility.
Subjects with COPD on LTOT had limited life-space mobility. Interventions to reduce dyspnea and improve exercise capacity should be prioritized to increase this population's domestic and community mobility.
活动能力是人体的各种形式的运动，包括从床到椅子的转移、行走、日常任务、参与工作和社交活动、锻炼以及使用公共交通工具。慢性阻塞性肺疾病（COPD）患者的活动能力会受到疾病症状的负面影响。然而，关于长期氧疗（LTOT）的COPD患者的生活空间活动能力的数据有限。本研究旨在探讨接受LTOT的COPD患者的生活空间活动能力，并验证生活空间活动能力是否与合并症、症状、日常生活活动、运动能力表现和生活质量相关。
这项横断面研究纳入了61例接受LTOT的COPD患者（年龄73.0±8.8岁，预计第一秒用力呼气容积[FEV]为41.7±16.0%，接受LTOT治疗2.8±3.3年）。评估了生活空间活动能力（生活空间评估）、LTOT使用时间、合并症（Charlson合并症指数）、对照顾者支持的需求、运动能力（6分钟步行试验）、呼吸困难（改良医学研究理事会量表）、日常生活活动（ADL，Katz量表）以及与健康相关的生活质量（欧洲五维健康量表）。
90%的参与者存在活动受限。生活空间活动能力与合并症数量呈负相关（r = -0.31，P = 0.02）、与呼吸困难症状呈负相关（r = -0.60，P < 0.001），与基本ADL表现呈正相关（r = 0.59，P < 0.001）以及与运动能力呈正相关（r = 0.49，P < 0.001）。呼吸困难和运动能力是生活空间活动能力的独立预测因素。
接受LTOT的COPD患者的生活空间活动能力有限。应优先采取干预措施以减轻呼吸困难并提高运动能力，从而增加该人群在家庭和社区中的活动能力。
